---
title: "Rheumatology Clinical Research Feed | MedicHelpline"
specialty: "Rheumatology"
specialty_slug: "rheumatology"
canonical_url: "https://medichelpline.com/clinical-feed/rheumatology"
content_type: "clinical_feed_specialty"
page: 1
articles_in_batch: 18
generated_at: "2026-09-05T23:52:20.377Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Rheumatology — Clinical Research Feed
## Specialty Overview: Rheumatology
Latest peer-reviewed clinical trials, guidelines, and observational research in **Rheumatology**, indexed and structured for clinical intelligence and AI reasoning.
## Latest Rheumatology Publications
### 1. [Single-cell genomics in rheumatoid arthritis: from synovial niches to new therapies](https://medichelpline.com/clinical-feed/nature-immunology-2-immune-mediated-rheumatoid-arthritis-from-single-cell-genomics-to-new-therapies.md)
- **Source:** Nature Immunology | **Published:** 2026-08-31
- **Detail Markdown URL:** [Single-cell genomics in rheumatoid arthritis: from synovial niches to new therapies](https://medichelpline.com/clinical-feed/nature-immunology-2-immune-mediated-rheumatoid-arthritis-from-single-cell-genomics-to-new-therapies.md)

> **Executive GIST:** - The application of **single-cell genomics** to immune-mediated arthritis has produced an extensive, rapidly expanding dataset that reveals diverse immune and stromal cell subsets in diseased joints. - Studies report novel **lymphocyte**, **myeloid** and **fibroblast** populations in the rheumatoid synovium that are proposed to have pathogenic roles. - Most single-cell findings are descriptive and correlative; a central challenge is converting these maps into mechanistic, causal insights relevant to disease pathogenesis. - Emerging approaches to address causality include **spatial transcriptomics** to define tissue niches, ex vivo mechanistic experiments, organoid models and cassette use of human-data–informed animal models. - Spatial methods reveal organized **synovial niches** and localized interactions among immune, stromal and endothelial cells that may drive pathology. - Ex vivo and organoid studies enable mechanistic interrogation of cell–cell interactions and functional states identified by single-cell profiling, bridging descriptive data and experimental manipulation. - Animal models that are better aligned to human synovial features informed by human single-cell data can help test hypotheses about drivers of disease and potential interventions. - Insights derived from integrating single-cell, spatial and mechanistic studies can guide the rational design of new therapeutic strategies and shape clinical trial approaches in **rheumatoid arthritis**. - The concepts and methods discussed for RA have potential applicability across other tissues and immune-mediated diseases, offering a general framework to translate high-resolution cellular maps into therapies. - Figures in the source highlight immune infiltration and expansion of the RA **synovium**, spatial transcriptomic identification of synovial niches, and modeling of niches in animal systems; the source emphasizes that the field must move from descriptive atlases toward causal and translational studies.

### 2. [Synovial Immune Control Failure in Osteoarthritis: From Homeostasis to Inflammatory Niche Formation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-synovial-immune-control-failure-in-osteoarthritis-from-maintenance-of-tissue.md)
- **Source:** Frontiers in Immunology | **Published:** 2026-08-31
- **Detail Markdown URL:** [Synovial Immune Control Failure in Osteoarthritis: From Homeostasis to Inflammatory Niche Formation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-synovial-immune-control-failure-in-osteoarthritis-from-maintenance-of-tissue.md)

> **Executive GIST:** - The source article metadata (title, journal, and URL) was provided but the full article body was not included; detailed findings, methods, and conclusions were not reported in the source text. - The article title indicates a focus on **synovial immune control** in **osteoarthritis** and a transition from normal tissue homeostasis to formation of an **inflammatory niche**, but the source did not supply supporting content or data. - Because the full manuscript content was absent, specifics such as implicated cell types, molecular pathways, experimental evidence, patient data, and proposed interventions were not available from the source. - The available information permits only an outline of likely topics: definitions of synovial immune regulation, concepts of tissue homeostasis, mechanisms that could underlie immune control failure, characteristics of an inflammatory niche, and clinical implications; however these are inferred from the title, not reported results. - Any detailed claims about mechanisms, biomarkers, or therapeutic strategies are not reported in the provided source and therefore cannot be stated with certainty. - The article’s provenance is Frontiers in Immunology; the source URL and journal metadata were given but content retrieval failed or was incomplete in the supplied SOURCE JINA BODY. - Readers and clinicians should consult the full published article for validated data, experimental design, and specific clinical or translational recommendations because those details were not available in the provided source.

### 3. [Acetylation-related biomarkers in osteoarthritis: bioinformatics identification of JUN and MYC](https://medichelpline.com/clinical-feed/plos-one-5-exploration-of-acetylation-related-biomarkers-in-osteoarthritis-through.md)
- **Source:** PLOS ONE (Medicine) | **Published:** 2026-08-28
- **Detail Markdown URL:** [Acetylation-related biomarkers in osteoarthritis: bioinformatics identification of JUN and MYC](https://medichelpline.com/clinical-feed/plos-one-5-exploration-of-acetylation-related-biomarkers-in-osteoarthritis-through.md)

> **Executive GIST:** - Osteoarthritis (OA) is a chronic degenerative joint disease with limited disease-modifying treatments; identification of biomarkers could improve diagnosis and therapy. - The study integrated synovial membrane microarray datasets GSE55235, GSE55457, and GSE12021 as a training cohort (29 OA, 29 controls) and used GSE82107 as a validation cohort (10 OA, 7 controls). - A list of **4,405 acetylation-related genes** was extracted from GeneCards using a relevance score cutoff > 2. - Differentially expressed genes (DEGs) were identified with |log2FC| > 0.5 and p < 0.05 using the limma package; functional enrichment (GO/KEGG) was performed on DEGs. - Weighted gene co-expression network analysis (**WGCNA**) was conducted with a soft threshold of 14, yielding five merged modules; the red module was selected as the core OA-associated module. - Intersection of core module genes, acetylation-related genes, and DEGs produced acetylation-related DEGs (ACEDEGs); a protein–protein interaction (PPI) network was built via STRING and analyzed in Cytoscape, with top genes prioritized by the MCC algorithm. - Three machine learning approaches (LASSO, Random Forest, XGBoost) were applied to refine hub gene selection. - A diagnostic prediction model (nomogram) was constructed and evaluated: training AUC = **0.983**, validation AUC = **0.743**. - Immune cell infiltration analyses using CIBERSORT revealed significant alterations in immune cell composition between OA and controls. - Experimental validation by qRT-PCR and Western blot confirmed down-regulation of **JUN** and **MYC** in OA synovial samples. - The study proposes **JUN** and **MYC** as novel acetylation-related biomarkers for OA and suggests potential roles in OA pathophysiology and diagnostics.

### 4. [Phycocyanobilin from Arthrospira platensis as a candidate LYN kinase modulator in systemic lupus e](https://medichelpline.com/clinical-feed/plos-one-15-phycocyanobilin-a-potential-bioactive-compound-from-arthrospira-platensis.md)
- **Source:** PLOS ONE (Medicine) | **Published:** 2026-08-28
- **Detail Markdown URL:** [Phycocyanobilin from Arthrospira platensis as a candidate LYN kinase modulator in systemic lupus e](https://medichelpline.com/clinical-feed/plos-one-15-phycocyanobilin-a-potential-bioactive-compound-from-arthrospira-platensis.md)

> **Executive GIST:** - This study investigated **phycocyanobilin**, a chromophore from Arthrospira platensis (Spirulina), for potential relevance to **systemic lupus erythematosus (SLE)** based on structural similarity to **bilirubin** (Tanimoto score 93%). - Researchers screened 833 algal-derived bioactive compounds against bilirubin using PubChem structural similarity tools and focused on phycocyanobilin due to its bile-pigment–like structure and prior network analyses. - Molecular docking (AutoDock/MGLTools) evaluated binding of phycocyanobilin and bilirubin to multiple protein targets previously implicated in SLE: **EGFR**, **FYN**, **HLA-B**, **LCK**, **LYN**, and **TP53**. - NetPredictor network-based target prediction prioritized **LYN kinase** as a key candidate receptor for phycocyanobilin. - Molecular dynamics (MD) simulations were run on the phycocyanobilin–LYN complex (LYN PDB ID 3A4O) for 60 ns with ff14SB force field in AMBER 16 at physiological conditions (300 K, 1 atm); the last 10 ns of trajectories were used for detailed analyses. - MD analyses included RMSD assessment for protein backbone, complex and ligand, hydrogen bond profiling, residue-level interaction mapping, and binding free energy estimation using MM/PBSA and MM/GBSA approaches. - Results indicated stable binding of phycocyanobilin to **LYN**, with interaction profiles comparable to the native ligand staurosporine; residue contributions and calculated binding free energies supported strong, stable interactions. - Authors conclude that phycocyanobilin may modulate **LYN-associated signaling pathways** relevant to SLE and recommend further investigation; specific numerical binding energies and some methodological parameters are reported in the full manuscript and supporting files. - Funding: none specific. Data: all relevant data are within the manuscript and supporting information. Competing interests: none declared.

### 5. [Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Moroccan Study](https://medichelpline.com/clinical-feed/medrxiv-12-real-world-effectiveness-and-safety-of-tocilizumab-in-refractory-rheumatoid.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-28
- **Detail Markdown URL:** [Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Moroccan Study](https://medichelpline.com/clinical-feed/medrxiv-12-real-world-effectiveness-and-safety-of-tocilizumab-in-refractory-rheumatoid.md)

> **Executive GIST:** - **Tocilizumab** (TCZ) is a monoclonal antibody targeting the interleukin-6 receptor, utilized in rheumatoid arthritis (RA). - This study evaluated TCZ's real-world effectiveness and safety in **44 Moroccan** RA patients after inadequate responses to previous treatments. - Conducted at Moulay Ismail Hospital, data was collected from **April 2019 to January 2024**. - 75% of participants were women, with a median age of **57** years and a mean RA duration of approximately **13 years**. - Prior to TCZ, patients had experienced on average **2.5** previous DMARDs and **93.2%** had received **biological agents**. - At the **6-month** mark, 67.6% achieved a good EULAR response while 35.3% attained **DAS28-ESR** remission. - Disease activity significantly decreased over the study period, indicated by reduced DAS28-ESR scores. - Adverse events included **22 infections**, with one serious that required hospitalization; liver enzyme changes were also noted. - Significant associations with EULAR response included **rheumatoid-factor positivity** and baseline tender joints. - Limitations include the study's retrospective nature and small sample size, suggesting findings are preliminary.

### 6. [FDA Approves Lisraya (brepocitinib) — First Oral Treatment for Adult Dermatomyositis](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-oral-drug-indicated-to-treat-dermatomyositis-in-adults.md)
- **Source:** FDA News Releases | **Published:** 2026-08-27
- **Detail Markdown URL:** [FDA Approves Lisraya (brepocitinib) — First Oral Treatment for Adult Dermatomyositis](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-oral-drug-indicated-to-treat-dermatomyositis-in-adults.md)

> **Executive GIST:** - The FDA approved **Lisraya** (brepocitinib) tablets as the first FDA‑approved oral therapy indicated for adults with **dermatomyositis**, addressing a long‑standing unmet need for this rare autoimmune disease. - Lisraya is a once‑daily oral **JAK/TYK2 inhibitor** that reduces immune‑mediated inflammation affecting skin and muscle. - Approval was based on a phase 3, randomized, double‑blind, multicenter, placebo‑controlled trial (NCT05437263) that enrolled 241 adults with dermatomyositis and evaluated treatment over 52 weeks. - Participants were randomized to brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo. - The primary efficacy measure included the **Total Improvement Score (TIS)** at week 52, a composite across six domains: muscle strength, physical function, skin and other disease activity, muscle enzymes, physician global assessment, and patient global assessment. - Lisraya 30 mg demonstrated a higher average TIS at week 52 versus placebo and showed improvements in physical function and skin disease activity; patients on the 30 mg dose were more likely to reduce corticosteroid use by week 48. - Common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea. - Discontinuations due to adverse reactions were 6% for Lisraya 30 mg versus 11% for placebo in the trial. - Lisraya carries a boxed warning for **serious infections**, increased **all‑cause mortality**, **malignancies**, **major adverse cardiovascular events**, and **thrombosis**. - The FDA granted Lisraya Orphan Drug and Priority Review designations. - The approval was granted to Priovant Therapeutics Inc. - The FDA statement emphasized that this approval provides an approved, evidence‑based oral option for clinicians and patients who previously relied on therapies intended for other conditions.

### 7. [Using MPRA and Human Expression Data to Identify Genetic Mechanisms in Juvenile Idiopathic Arthrit](https://medichelpline.com/clinical-feed/medrxiv-16-combining-a-massively-parallel-reporter-assay-and-human-data-to-elucidate.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-27
- **Detail Markdown URL:** [Using MPRA and Human Expression Data to Identify Genetic Mechanisms in Juvenile Idiopathic Arthrit](https://medichelpline.com/clinical-feed/medrxiv-16-combining-a-massively-parallel-reporter-assay-and-human-data-to-elucidate.md)

> **Executive GIST:** - The study combined previously published **massively parallel reporter assay (MPRA)** results with human expression datasets to identify cells and target genes affected by JIA-associated SNPs. - MPRA-identified single nucleotide polymorphisms (SNPs) were queried against the Database of Immune Cell eQTLs (DICE) and the Genotype-Tissue Expression (GTEx) resource. - MPRA SNPs showed associations with gene expression across multiple immune cell types in DICE, including **CD4+ and CD8+ T cells**, monocytes, natural killer cells, and B cells. - In GTEx, the same MPRA-identified SNPs had strong expression associations in **whole blood**, spleen, and Epstein–Barr virus (EBV)-stimulated lymphocyte samples. - Findings support the effectiveness of integrating MPRA functional screens with human cell and tissue eQTL data to elucidate complex genetic risk mechanisms for juvenile idiopathic arthritis (JIA). - Data provenance and reproducibility: the original MPRA sequencing data are available under SRA accession PRJNA818294. - The report emphasizes that while MPRA can nominate functional variants, identifying affected cell types and target genes benefits from cross-referencing with human eQTL resources. - Authors declared no competing interests and stated appropriate ethical approvals and participant consent; funding reported from NIH grants R21-AR071878 and R01AR078785.

### 8. [CD19 CAR T-cell therapy (mivocabtagene autoleucel) in refractory seropositive rheumatoid arthritis](https://medichelpline.com/clinical-feed/nature-1-cd19-car-t-cell-therapy-for-treatment-refractory-seropositive-rheumatoid.md)
- **Source:** Nature Medicine | **Published:** 2026-08-27
- **Detail Markdown URL:** [CD19 CAR T-cell therapy (mivocabtagene autoleucel) in refractory seropositive rheumatoid arthritis](https://medichelpline.com/clinical-feed/nature-1-cd19-car-t-cell-therapy-for-treatment-refractory-seropositive-rheumatoid.md)

> **Executive GIST:** - This report presents the phase 1 portion of the COMPARE trial testing autologous fully human **CD19 CAR T cell** therapy, mivocabtagene autoleucel (**miv-cel**), in treatment-refractory, seropositive rheumatoid arthritis (RA). - Six patients (three men, three women) with severe, treatment-refractory, anti-citrullinated protein antibody (**ACPA**)-positive RA received a single infusion of miv-cel after stopping all disease-modifying antirheumatic drugs and standard lymphodepletion. - Patients were followed for 36–52 weeks for safety and efficacy; primary endpoints were incidence and severity of **cytokine release syndrome (CRS)**, immune effector cell-associated neurotoxicity syndrome (ICANS) and adverse events (AEs) within 4 weeks post-treatment. - **CRS** occurred in all six patients but was limited to grade 1–2 events. No ICANS or serious AEs were reported during the primary safety window. - One dose-limiting toxicity (DLT) occurred: a grade 3 transaminase elevation that resolved without sequelae. - CAR T cell infusion produced depletion of **CD19+ B cells** in blood and tissue and a continuous decline in autoantibody titers. - Seroconversion was observed for autoantibodies in several patients: four of six for ACPAs against mutated citrullinated vimentin and five of six for rheumatoid factor (IgM). - Clinical disease activity improved in all patients despite cessation of immunosuppressive therapies, with a median 34% reduction in **DAS28-CRP** at latest follow-up; three of six patients achieved DAS28-CRP remission and ACR70 response. - Short-term tolerability was acceptable, meeting the primary safety endpoint and supporting progression to the phase 2 component. - ClinicalTrials.gov identifier reported: NCT06475495.

### 9. [Monocyte reprogramming after autologous stem cell transplantation in juvenile systemic sclerosis:](https://medichelpline.com/clinical-feed/biorxiv-4-longitudinal-single-cell-modeling-reveals-monocyte-reprogramming-in-juvenile.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-26
- **Detail Markdown URL:** [Monocyte reprogramming after autologous stem cell transplantation in juvenile systemic sclerosis:](https://medichelpline.com/clinical-feed/biorxiv-4-longitudinal-single-cell-modeling-reveals-monocyte-reprogramming-in-juvenile.md)

> **Executive GIST:** - Juvenile systemic sclerosis (jSSc) is a rare autoimmune condition with skin fibrosis and multi-organ involvement; autologous stem cell transplantation (ASCT) is an emerging therapy for severe, refractory disease. - The study collected PBMCs from three jSSc patients before ASCT and at 6, 12, and 24 months after ASCT, with healthy control samples for comparison. - Samples were profiled using **CITE-seq** (cellular indexing of transcriptomes and epitopes by sequencing) to capture joint RNA and protein signal at single-cell resolution. - Analyses focused on **monocytes** because of their recognized role in fibrosis-promoting inflammation in systemic sclerosis. - A longitudinal modeling approach regressed pseudobulked (log-scale) gene expression against time since ASCT to detect temporal trends across patients. - Key gene-level findings included decreased expression, after ASCT, of systemic sclerosis–linked genes such as **SERPINE1** in monocytes. - Pathway-level results showed elevated **NF-κB**–associated inflammatory signaling in jSSc monocytes at baseline versus healthy controls, with progressive decreases following ASCT. - Genes related to mitochondrial function and **oxidative phosphorylation** increased progressively after ASCT, suggesting a metabolic shift in monocytes posttransplant. - Compositional changes in monocyte subpopulations were observed and may have contributed to the longitudinal gene expression dynamics. - The study presents both immunologic insights into jSSc response to ASCT and a broadly applicable longitudinal single-cell modeling framework. The authors provided code on GitHub and reported funding sources; no competing interests were declared.

### 10. [Estrogen–Ferroptosis Axis in Postmenopausal Osteoporosis, Osteoarthritis, and Disc Degeneration](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-the-estrogen-ferroptosis-axis-in-postmenopausal-osteoporosis-osteoarthritis-and.md)
- **Source:** Frontiers in Immunology | **Published:** 2026-08-26
- **Detail Markdown URL:** [Estrogen–Ferroptosis Axis in Postmenopausal Osteoporosis, Osteoarthritis, and Disc Degeneration](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-the-estrogen-ferroptosis-axis-in-postmenopausal-osteoporosis-osteoarthritis-and.md)

> **Executive GIST:** - The full article text and substantive content were not available in the provided source excerpt; only journal navigation and metadata were present. - The original article title indicates a focus on the **estrogen–ferroptosis axis** as it relates to three conditions: **postmenopausal osteoporosis**, **osteoarthritis**, and **intervertebral disc degeneration**. - Because the body text was missing, specific mechanisms, experimental data, study designs, outcomes, and authors' conclusions were not reported in the source and cannot be summarized or inferred. - Key terms signaled by the title that would be central to any review include **estrogen**, **ferroptosis**, and the three musculoskeletal conditions named above, but detailed interactions or evidence linking these concepts were not provided. - The absence of article content means clinical implications, therapeutic suggestions, and research gaps reported by the authors are not available from the provided source. - Any synthesis or recommendations beyond the title would require access to the full article; readers should consult the original Frontiers in Immunology article for complete data and conclusions.

### 11. [Nociplastic Pain Phenotypes in Systemic Lupus Erythematosus: Longitudinal Registry Analysis](https://medichelpline.com/clinical-feed/medrxiv-22-longitudinal-characterization-of-nociplastic-pain-in-systemic-lupus.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-23
- **Detail Markdown URL:** [Nociplastic Pain Phenotypes in Systemic Lupus Erythematosus: Longitudinal Registry Analysis](https://medichelpline.com/clinical-feed/medrxiv-22-longitudinal-characterization-of-nociplastic-pain-in-systemic-lupus.md)

> **Executive GIST:** - This nationwide registry study used FORWARD Databank data to classify SLE patients into four nociplastic pain phenotypes—**Minimal**, **Type 1**, **Type 2**, and **Mixed**—using the Polysymptomatic Distress Scale (PSD≥8) and the Systemic Lupus Activity Questionnaire (SLAQ) inflammatory domain (≥2). - Cross-sectional sample included 372 patients; longitudinal analyses used 301 patients with a median follow-up of 3.7 years. - Baseline distribution: 29% Minimal, 12% Type 1, 13% Type 2, and 47% Mixed. - Functional impairment tracked stepwise by phenotype: SF-36 physical component scores fell and PROMIS Pain Interference scores rose from Minimal to Mixed (SF-36 49.7 to 30.0; PROMIS 46.2 to 63.6; both p<0.001). - **Mixed** phenotype showed the highest organ damage, depression, and opioid use at baseline. - Longitudinal persistence differed by phenotype: Minimal and Mixed were relatively persistent (mean duration ~2.0 and 1.8 years; one-year retention ~70%), while Type 1 and Type 2 tended to be transient (~0.5 years; one-year retention 18% and 28%). - Transition patterns were asymmetric: Type 1 most often transitioned to Minimal (49% of exits); Type 2 most often transitioned to Mixed (65% of exits; p<0.001). - Population-average PSD was essentially stable over time (+0.014 SD/year, p=0.07). - Opioid use declined to near zero over time among Minimal and Type 1 groups but remained elevated in Type 2 and Mixed groups. - Joint group-based trajectory modeling (GBTM) identified four severity classes arrayed along a Minimal-to-Mixed diagonal, supporting a severity-stratified structure of nociplastic phenotypes in SLE. - Overall, nociplastic phenotypes in SLE are clinically meaningful, persistent for some phenotypes, and associated with differing functional, psychological, organ-damage, and opioid burdens. - Data are available from FORWARD upon request; analytic code is available from the corresponding author upon request. Ethical approval was provided by Solutions IRB. The report is a preprint and not peer-reviewed.

### 12. [Post-translational neoantigens in rheumatoid arthritis: molecular mechanisms and therapeutic impli](https://medichelpline.com/clinical-feed/frontiers-in-immunology-9-molecular-basis-of-post-translational-neoantigen-generation-in-rheumatoid.md)
- **Source:** Frontiers in Immunology | **Published:** 2026-08-20
- **Detail Markdown URL:** [Post-translational neoantigens in rheumatoid arthritis: molecular mechanisms and therapeutic impli](https://medichelpline.com/clinical-feed/frontiers-in-immunology-9-molecular-basis-of-post-translational-neoantigen-generation-in-rheumatoid.md)

> **Executive GIST:** - Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease driven by loss of immune tolerance to self-antigens, often affecting small and medium joints and producing extra-articular manifestations. Genetic susceptibility (eg, HLA-DRB1) and environmental triggers interact to induce disease. - **Post-translational modifications (PTMs)** — including **citrullination**, **carbamylation**, **glycosylation**, and glycation/AGE formation — generate altered self-proteins (neoantigens) with increased immunogenicity under conditions of inflammation and oxidative stress. - Enzymes such as peptidylarginine deiminases (PADs) and transglutaminases, reactive oxygen species (ROS), neutrophil activation and NET formation promote PTMs in synovium and mucosal tissues like lung and periodontal mucosa. - PTM-derived neoantigens are processed and presented by antigen-presenting cells via MHC class II to autoreactive CD4+ T cells, driving B-cell activation and production of autoantibodies including **ACPAs** and anti-CarP antibodies; immune complexes, complement activation and cytokines amplify synovial inflammation. - Chronic inflammation in RA associates with expansion and activation of synovial cell types (fibroblast-like synoviocytes, macrophage-like synoviocytes), ectopic germinal centers, Treg dysfunction and Th17 skewing, all facilitating epitope spreading and persistent joint damage. - Proteomic surveys and targeted mass spectrometry have directly identified multiple PTM-modified proteins in RA tissues and fluids (eg, citrullinated β-actin, vimentin; carbamylated albumin, collagen II; aberrantly glycosylated IgG), summarized in the review’s Table 1. - PTMs can create peptides absent during central tolerance, so peripheral modification can render self-Ags “nonself”; T-cell responses often recognize only the modified peptide while B-cell responses may cross-react with unmodified forms. - Recognizing PTM-derived neoantigens has diagnostic and prognostic potential and supports development of precision therapies aimed at interrupting neoantigen generation or restoring antigen-specific tolerance. - Emerging targeted approaches discussed include antigen-specific tolerogenic vaccines, tolerogenic dendritic cells, adoptive regulatory cell therapies (CAR-Tregs, antigen-specific Tregs), inhibitors of PTM enzymes (eg, PAD inhibitors), and NET-targeting strategies (eg, DNase I, CIT-013) intended to limit synovial inflammation while reducing systemic immunosuppression. - The review emphasizes that deeper molecular characterization of PTM neoantigens could refine diagnostics and enable more selective treatments, but it notes that many mechanistic details and clinical translation remain areas of active research.

### 13. [FDA clears Regeneron’s Pasatru for fibrodysplasia ossificans progressiva, halting new bone growth](https://medichelpline.com/clinical-feed/stat-news-2-stat-regeneron-drug-for-disease-that-causes-dangerous-bone-growth-earns-fda.md)
- **Source:** STAT News | **Published:** 2026-08-19
- **Detail Markdown URL:** [FDA clears Regeneron’s Pasatru for fibrodysplasia ossificans progressiva, halting new bone growth](https://medichelpline.com/clinical-feed/stat-news-2-stat-regeneron-drug-for-disease-that-causes-dangerous-bone-growth-earns-fda.md)

> **Executive GIST:** - Regeneron’s medicine, **Pasatru**, received FDA approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder that causes bone to form in soft tissues. - The approval caps roughly a three-decade effort to develop a therapy for the condition. - In the pivotal trial referenced by the source, the medicine “drastically cut the risk of new bone formation.” - Investigators, including Richard Keen of the Royal National Orthopaedic Hospital, described the effect as nearly stopping new bone formation, with the potential to halt clinical deterioration. - Clinicians hope the treatment will help patients preserve mobility and possibly extend life expectancy compared with the natural history of FOP. - The article notes typical disease milestones: many people with FOP rely on wheelchairs by about age 25, and only some survive into their 50s. - The STAT article reporting the approval was a STAT+ exclusive; the full report and many trial details were behind a subscriber paywall. - The source did not provide specific regulatory documents, dosing, trial size, statistical outcomes, safety data, or the FDA-approved indication text; those details were not reported in the portion of the article provided.

### 14. [Boric Acid Protects Human Chondrocytes From LPS-Induced Inflammation and Apoptosis](https://medichelpline.com/clinical-feed/biorxiv-18-protective-effects-of-boric-acid-against-lps-induced-inflammation-and-apoptosis.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-18
- **Detail Markdown URL:** [Boric Acid Protects Human Chondrocytes From LPS-Induced Inflammation and Apoptosis](https://medichelpline.com/clinical-feed/biorxiv-18-protective-effects-of-boric-acid-against-lps-induced-inflammation-and-apoptosis.md)

> **Executive GIST:** - Osteoarthritis involves **inflammation**, chondrocyte dysfunction, and progressive cartilage breakdown; the study examined whether **boric acid (BA)** can protect primary human articular chondrocytes from inflammatory injury induced by lipopolysaccharide (LPS). - Primary human chondrocytes were exposed to LPS to model inflammatory injury; outcomes measured included cell survival, membrane integrity, **apoptosis**, production of inflammatory mediators, nitrite levels, and expression of genes linked to inflammation and extracellular matrix degradation. - Treatment with BA improved chondrocyte survival after LPS stimulation and reduced membrane damage and apoptotic cell death compared with LPS alone. - BA suppressed expression of inflammatory and matrix-degrading genes and decreased nitrite production and release of pro-inflammatory mediators in the inflamed chondrocytes. - Protective effects were dose-dependent within the tested range: higher BA treatment produced generally stronger suppression of inflammatory and catabolic responses. - Publicly available human chondrocyte RNA-sequencing datasets were analyzed and provided complementary support for the relevance of several inflammatory and catabolic targets assessed in the experimental model. - Authors conclude that BA exerts **chondroprotective** effects against LPS-induced inflammatory and catabolic injury in primary human chondrocytes and recommend further investigation of BA as a potential approach in osteoarthritis. - The study is a preprint posted on bioRxiv (doi: https://doi.org/10.64898/2026.08.13.744490); competing interests were declared as none. Details such as exact BA doses, timepoints, sample size, and statistical measures were not reported in the source summary.

### 15. [Modulating the Chondro‑Fibro Axis to Improve Volumetric Cartilage Repair After Microfracture](https://medichelpline.com/clinical-feed/biorxiv-2-directing-the-chondro-fibro-axis-via-early-microenvironmental-interactions-to.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-15
- **Detail Markdown URL:** [Modulating the Chondro‑Fibro Axis to Improve Volumetric Cartilage Repair After Microfracture](https://medichelpline.com/clinical-feed/biorxiv-2-directing-the-chondro-fibro-axis-via-early-microenvironmental-interactions-to.md)

> **Executive GIST:** - Cartilage repair using **microfracture (MFx)** often fails because the MFx clot contracts and is replaced by fibrotic tissue, producing inadequate defect fill and poor repair quality. These deleterious processes are evident as early as one week in multiple animal models, including minipigs. - The study tested whether directing early **microenvironmental interactions** in the MFx clot could preserve clot volume and reprogram marrow-derived cells (MDCs) from a fibrotic/myofibroblast fate toward chondrogenesis. - Extracellular approaches—augmenting **fibrinogen** or applying anti-fibrinolytic treatment—reduced clot contraction but did not reduce, and in some cases increased, the fibrotic susceptibility of MDCs. - Intracellular manipulation of cell–environment signaling via the **Rho‑ROCK** pathway altered how MDCs responded to **TGF‑B3**, creating a continuum described as a **chondro‑fibro axis**. - Pharmacologic inhibition of ROCK with **Fasudil** shifted TGF‑B3–treated MDCs away from a myofibroblast phenotype and toward chondrogenic behavior, reducing macroscale clot contraction in short-term in vitro experiments and enhancing cartilage-specific matrix deposition. - A pilot rat study combining Fasudil with TGF‑B3 improved glycosaminoglycan (GAG) deposition within defects and conferred better protection to surrounding cartilage compared with controls. - The authors propose that precise control of Rho‑ROCK modulation of TGF signaling in the MFx clot may be a promising strategy to achieve more precise, volumetric cartilage repair by leveraging early microenvironmental interactions. - Patent disclosures and funding sources were reported; specific experimental protocols, quantitative metrics, long-term outcomes and broader translational steps were not detailed in the source abstract and require consultation of the full manuscript or supplementary materials for further specifics.

### 16. [Avacopan Readjudication Confirms Noninferiority for ANCA-Associated Vasculitis Remission](https://medichelpline.com/clinical-feed/medrxiv-0-avacopan-for-the-treatment-of-anca-associated-vasculitis-the-primary-endpoints.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-14
- **Detail Markdown URL:** [Avacopan Readjudication Confirms Noninferiority for ANCA-Associated Vasculitis Remission](https://medichelpline.com/clinical-feed/medrxiv-0-avacopan-for-the-treatment-of-anca-associated-vasculitis-the-primary-endpoints.md)

> **Executive GIST:** - The phase 3 ADVOCATE trial evaluated oral **avacopan** 30 mg twice daily versus a scheduled oral **prednisone** taper, each with rituximab- or cyclophosphamide-based standard of care, in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). - Concerns about the original 2019 primary endpoint adjudication prompted a blinded independent readjudication in 2026 by the Duke Clinical Research Institute Clinical Events Classification group using procedures aligned with the original charter. - The primary endpoints were **remission at week 26** and **sustained remission at week 52**, adjudicated using the Birmingham Vasculitis Activity Score (BVAS) and definitions of relapse and remission. - In the 2026 readjudication (intent-to-treat, n=330), remission at week 26 was 68.1% (113/166) with avacopan and 67.1% (110/164) with prednisone (adjusted difference 2.2%; 95% CI, −7.5 to 11.9), confirming noninferiority per the prespecified −20 percentage point margin. - Sustained remission at week 52 in 2026 was 61.4% (102/166) with avacopan versus 52.4% (86/164) with prednisone (adjusted difference 9.8%; 95% CI, −0.3 to 19.9); this numeric advantage did not meet statistical superiority. - Results are similar to the 2019 adjudication: week 26 remission 72.3% vs 70.1% (adjusted difference 3.4%; 95% CI, −6.0 to 12.8) and week 52 sustained remission 65.7% vs 54.9% (adjusted difference 12.5%; 95% CI, 2.6 to 22.3). - Concordance between 2019 and 2026 adjudications was high: 95.2% for remission and 93.6% for sustained remission. - The readjudication confirms **noninferiority of avacopan** at weeks 26 and 52 while noting a median 81% reduction in glucocorticoid exposure in the avacopan group compared with the prednisone taper group. - Although a consistent numerical advantage for avacopan at week 52 was present in both adjudications, statistical superiority was not achieved in the 2026 re-analysis. - The report details competing interests for multiple authors and states that trial data are not publicly available; qualified researchers may request access under governance procedures.

### 17. [Secukinumab Phase 3 Trial Shows Higher Remission and Lower Glucocorticoid Use in Relapsing Polymya](https://medichelpline.com/clinical-feed/pubmed-42234540.md)
- **Source:** PubMed / NCBI | **Published:** 2026-08-13 | DOI: [10.1056/NEJMoa2602567](https://doi.org/10.1056%2FNEJMoa2602567)
- **Detail Markdown URL:** [Secukinumab Phase 3 Trial Shows Higher Remission and Lower Glucocorticoid Use in Relapsing Polymya](https://medichelpline.com/clinical-feed/pubmed-42234540.md)

> **Executive GIST:** - This Phase 3, randomized, double-blind trial evaluated **secukinumab** (300 mg and 150 mg) versus placebo in patients with recently relapsed **polymyalgia rheumatica** receiving a 24-week prednisone taper. - A total of 381 patients were randomized 1:1:1 (127 per group) and followed for 52 weeks; the study is reported under the REPLENISH program (ClinicalTrials.gov NCT05767034). - The primary outcome was **sustained remission** at week 52, defined as remission from week 12 through week 52 without signs or symptoms attributable to polymyalgia rheumatica and without a new diagnosis of giant-cell arteritis that required escape/rescue treatment. - Sustained remission rates at 52 weeks were 41.2% (SEC-300), 40.6% (SEC-150), and 20.4% (placebo); both secukinumab doses were statistically superior to placebo (P<0.001 vs placebo for each dose). - Mean adjusted annual cumulative glucocorticoid dose was lower in the secukinumab groups (1603.7 mg for SEC-300; 1683.2 mg for SEC-150) than in placebo (2093.0 mg). - Serious adverse event rates were similar across groups (13.5% SEC-300; 15.9% SEC-150; 14.2% placebo). Certain adverse events — nasopharyngitis, hypersensitivity reactions, urinary tract infections, fungal infections, and back pain — were more common with secukinumab than with placebo. - The trial concludes that adding **secukinumab** to a 24-week glucocorticoid taper increased remission rates and reduced cumulative glucocorticoid exposure versus taper alone in relapsed polymyalgia rheumatica. - Funding was provided by Novartis. Additional protocol details, longer-term follow-up beyond 52 weeks, and subgroup analyses were not reported in the source abstract.

### 18. [Boulevard Bio co-founded by Georg Schett pivots to antibody therapies, not CAR-T](https://medichelpline.com/clinical-feed/stat-news-2-stat-biotech-company-co-founded-by-top-autoimmune-researcher-lays-out-plans.md)
- **Source:** STAT News | **Published:** 2026-08-12
- **Detail Markdown URL:** [Boulevard Bio co-founded by Georg Schett pivots to antibody therapies, not CAR-T](https://medichelpline.com/clinical-feed/stat-news-2-stat-biotech-company-co-founded-by-top-autoimmune-researcher-lays-out-plans.md)

> **Executive GIST:** - Georg Schett, a German autoimmune disease researcher known for pioneering work showing that **CAR-T** therapy can reset patients’ immune systems, is a co-founder of a new biotech, Boulevard Bio. - Schett has spent the past five years building a reputation in autoimmune therapeutics and serving as a scientific adviser to multiple startups; this is his first time co-founding a company. - Boulevard Bio’s initial public plan is to develop **antibody therapies**, and the company does not intend to pursue **CAR-T** approaches immediately. - The reporting is from STAT News (STAT+ exclusive) and was written by Allison DeAngelis on Aug. 12, 2026. - The article notes Schett’s shift in focus from CAR-T to antibodies but does not disclose detailed program-level information such as specific targets, preclinical or clinical status, funding amounts, leadership team composition beyond Schett, or timelines. - STAT’s piece is available behind a STAT+ paywall; subscribers can access the full exclusive coverage. The publicly available portion emphasizes Schett’s profile, his CAR-T findings, and the novel decision to co-found Boulevard Bio with an antibody-first strategy. - Important context reported: Schett’s CAR-T findings previously suggested potential to “reset” immune systems in autoimmune disease, which elevated his visibility and led to advisory roles across multiple startups. - The article frames Boulevard Bio’s approach as a noteworthy strategic pivot given Schett’s CAR-T association, but it does not provide clinical or scientific data on the company’s antibody programs. - The source lists topic tags including autoimmune, biotechnology, chronic diseases, and drug development, indicating the story’s relevance to autoimmune and therapeutic development communities. - Where the source is incomplete, specific operational and scientific details were not reported in the accessible portion of the article and therefore are noted as unavailable from the source.

## Machine-Readable Pagination & Traversal
- [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md)
- [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/rheumatology.md?page=2)
## Other Clinical Specialties
- [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md)
- [Public Health](https://medichelpline.com/clinical-feed/public-health.md)
- [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.